Ambrilia grants TaiMed exclusive, worldwide rights to develop, manufacture and commercialize protease inhibitor (PI) and integrase inhibitor programs to treat HIV/AIDS

Ambrilia Biopharma Inc.

Canada / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

TaiMed Biologics Inc.

Taiwan / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced